Yes, Gilead put superhigh prices on hep C drugs, but what can you do? Senators ask

Eric Palmer After 18 months spent slicing and dicing 20,000 pages of Gilead Sciences documents and emails, a Senate investigation concluded that the drugmaker put very high price tags ...

Flailing MannKind makes a murky move to stay afloat, signing away pipeline drugs

Damian Garde MannKind, decimated by the departure of former co-signer Sanofi, is trying to conserve value in the face of sluggish sales for its inhaled insulin, signing a deal to transfer ...

GAO report hammers FDA for lax oversight on speedily approved drugs

Carly Helfand These days, the FDA is approving more and more drugs under its expedited programs, meaning new treatments are getting to patients faster. The problem? The agency ...

Money-back guarantees on cancer drugs are real in Italy, and the world is watching

Tracy Staton One country is ahead of the curve in striking pay-for-performance deals on cancer drugs–and, more importantly, collecting the cash when treatments don't hit their ...

Don’t split up the dynamic duo of GSK’s vaccines and drugs, vax chief says

Carly Helfand Prominent U.K. investor Neil Woodford has been calling for a four-way breakup of GlaxoSmithKline, a company he says is too "complicated" for its own good. But ...

Cipla says top 50 drugs in development could bring in $30B

John Carroll Indian drugmaker Cipla said it currently has 200 drugs in development and that the top 50 of those drugs have the potential to earn the company more than $ 30 billion. FierceBiotech ...

Onslaught of new drugs will shake up MS, diabetes, cancer and more

Tracy Staton A bumper crop of FDA approvals in 2015 means an equal number of launches to keep an eye on in 2016. Last year, FiercePharmaMarketing brought you a list of 8 markets to ...

Australia bets $1B on pricey hep C drugs in broad effort to eradicate the disease

Carly Helfand Good news for Gilead Sciences and Bristol-Myers Squibb: Australia's federal government wants to eliminate hepatitis C in the country. And it plans to shell out $ ...

Pharma’s newest nemesis? Nestlé works at the intersection of food and drugs to attack illnesses

Eric Palmer If Big Pharma didn't already have enough to worry about, with patent cliffs, drug price investigations and reluctant payers, it now will have to face the onslaught of ...

Allergan recalls eye drugs after patients complain of particles, blurred vision

Carly Helfand Since Allergan and Actavis joined hands to become a new-look Allergan, the company has already had to recall a from the Actavis side. Now, it's recalling one from ...

NICE plots takeover of England’s Cancer Drugs Fund

Emily Wasserman England's Cancer Drugs Fund has been dealing with budget overruns and backlash from drugmakers and patients unhappy with the fund's decision to ax certain meds ...

Cannabis patch startup pulls off a $42M IPO to fund drugs for epilepsy, pain

Damian Garde Pennsylvania drugmaker Zynerba Pharmaceuticals is making its way to Wall Street with some cannabis-derived treatments for central nervous system disorders, raising $ 42 ...
Page 1 of 1212345...10...Last »
© 2017 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS